In this work, we propose a tumor-specific expression strategy utilizing tumor-specific gene nanomedicines to drive tumor cells to secrete CXCL9 and anti-PD-L1 scFv (αPD-L1), thereby forming high intratumoral concentrations of CXCL9 and αPD-L1 for T-cell recruitment and PD-L1 blockade, respectively (Fig. 1). The gene discussed is CD274; the disease is neoplasm.